产碳青霉烯酶肺炎克雷伯菌的双重碳青霉烯类治疗。
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.
机构信息
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA.
出版信息
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. doi: 10.1128/AAC.01420-10. Epub 2011 Mar 21.
Abstract
The limited treatment options available for carbapenemase-producing Klebsiella pneumoniae (KPC) have made it a formidable pathogen. Previously we have shown the enhanced activity of pharmacodynamically optimized doripenem against KPC. Capitalizing on KPC's increased affinity for ertapenem, we evaluated the efficacy of a combination of ertapenem and doripenem in both an in vitro chemostat and an in vivo murine thigh infection model. Overall, the combination of doripenem plus ertapenem demonstrated enhanced efficacy over either agent alone.
摘要
可供治疗产碳青霉烯酶肺炎克雷伯菌（KPC）的方法有限，使其成为一种棘手的病原体。此前我们已经证实，对药效学进行优化的多利培南对 KPC 的活性增强。利用 KPC 对厄他培南的亲和力增加，我们评估了厄他培南和多利培南联合使用在体外恒化器和体内小鼠大腿感染模型中的疗效。总的来说，多利培南联合厄他培南的疗效优于单独使用任一药物。
相似文献
1
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. doi: 10.1128/AAC.01420-10. Epub 2011 Mar 21.
2
Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.
Int J Antimicrob Agents. 2013 Jun;41(6):582-5. doi: 10.1016/j.ijantimicag.2013.02.015. Epub 2013 Apr 21.
3
Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model.
Antimicrob Agents Chemother. 2013 Aug;57(8):3936-40. doi: 10.1128/AAC.00708-13. Epub 2013 Jun 3.
4
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
J Antimicrob Chemother. 2013 Jul;68(7):1616-8. doi: 10.1093/jac/dkt056. Epub 2013 Mar 8.
5
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Antimicrob Agents Chemother. 2014;58(3):1678-83. doi: 10.1128/AAC.01947-13. Epub 2013 Dec 30.
6
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
J Antimicrob Chemother. 2017 Jul 1;72(7):1981-1984. doi: 10.1093/jac/dkx084.
7
Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2013 May;57(5):2388-90. doi: 10.1128/AAC.02399-12. Epub 2013 Feb 25.
8
In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
J Antimicrob Chemother. 2016 Jan;71(1):156-61. doi: 10.1093/jac/dkv294. Epub 2015 Sep 27.
9
Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae.
J Med Microbiol. 2009 Oct;58(Pt 10):1303-1308. doi: 10.1099/jmm.0.012575-0. Epub 2009 Jun 25.
10
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
引用本文的文献
1
Strategic re-engineering of antibiotics.
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
2
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
3
Multidrug resistant : A study on its pathogenesis and therapeutics.
Curr Res Microb Sci. 2024 Dec 6;8:100331. doi: 10.1016/j.crmicr.2024.100331. eCollection 2025.
4
In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Pseudomonas aeruginosa.
J Antimicrob Chemother. 2025 Feb 3;80(2):593-595. doi: 10.1093/jac/dkae445.
5
Carbapenem-Resistant in COVID-19 Era-Challenges and Solutions.
Antibiotics (Basel). 2023 Aug 4;12(8):1285. doi: 10.3390/antibiotics12081285.
6
Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.
Antibiotics (Basel). 2023 Jul 31;12(8):1262. doi: 10.3390/antibiotics12081262.
7
Dual beta-lactam treatment: Pros and cons.
Porto Biomed J. 2022 Oct 24;7(5):e189. doi: 10.1097/j.pbj.0000000000000189. eCollection 2022 Sep-Oct.
8
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
Clin Infect Dis. 2023 May 1;76(Suppl 2):S179-S193. doi: 10.1093/cid/ciad094.
9
Evaluation of In Vitro Activity of Double-Carbapenem Combinations against KPC-2-, OXA-48- and NDM-Producing and .
Antibiotics (Basel). 2022 Nov 17;11(11):1646. doi: 10.3390/antibiotics11111646.
10
Carbapenem-Only Combination Therapy against Multi-Drug Resistant : Assessment of In Vitro and In Vivo Efficacy and Mode of Action.
Antibiotics (Basel). 2022 Oct 25;11(11):1467. doi: 10.3390/antibiotics11111467.
本文引用的文献
1
Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin.
J Hosp Infect. 2010 Sep;76(1):70-3. doi: 10.1016/j.jhin.2010.03.021. Epub 2010 Jun 17.
2
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
3
Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary.
Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):765-9. doi: 10.1007/s10096-010-0921-3. Epub 2010 Apr 18.
4
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2010 Feb;54(2):804-10. doi: 10.1128/AAC.01190-09. Epub 2009 Dec 7.
5
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Oct;53(10):4352-6. doi: 10.1128/AAC.00282-09.
6
Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns.
Infect Control Hosp Epidemiol. 2009 Jul;30(7):666-71. doi: 10.1086/598244.
7
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrob Agents Chemother. 2008 Feb;52(2):570-3. doi: 10.1128/AAC.01114-07. Epub 2007 Dec 10.
8
Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
Diagn Microbiol Infect Dis. 2007 Dec;59(4):425-32. doi: 10.1016/j.diagmicrobio.2007.05.009. Epub 2007 Jul 26.
9
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.
J Clin Microbiol. 2007 Aug;45(8):2723-5. doi: 10.1128/JCM.00015-07. Epub 2007 Jun 20.
10
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
Antimicrob Agents Chemother. 2007 Apr;51(4):1481-6. doi: 10.1128/AAC.00752-06. Epub 2007 Feb 5.
Zotero 插件